A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis

Last updated: July 8, 2019
Sponsor: Starpharma Pty Ltd
Overall Status: Completed

Phase

3

Condition

Sexually Transmitted Diseases (Stds)

Vaginal Infection

Gynecological Infections

Treatment

N/A

Clinical Study ID

NCT01577537
SPL7013-016
  • Ages > 12
  • Female

Study Summary

The primary objective of the study is to assess the efficacy of 1% SPL7013 Gel compared to placebo gel for the treatment of bacterial vaginosis (BV).

After screening eligible participants will be randomized to receive either 1% SPL7013 Gel or hydroxyethyl cellulose (HEC) placebo gel at a dose of 5g administered vaginally at bedtime for 7 consecutive days. Participants will be assessed for BV (both by Amsel criteria and Nugent score) at screening/Baseline, after last application (End of Treatment, EOT, Day 9-12) and at the final study visit approximately 2-3 weeks after last dose (Test of Cure, TOC, Day 21-30).

Eligibility Criteria

Inclusion

Key eligibility criteria:

  • Post-menarchal females, aged 12 years or more

  • Diagnosis of BV by Amsel criteria (ie all four of the following signs/symptoms: presence of white to grey homogeneous discharge; positive whiff test indicating an amine (fishy) odor with addition of potassium hydroxide; vaginal pH greater than 4.5; and presence at least 20% clue cells of total epithelial cells

  • Nugent score of at least 4

  • Otherwise healthy, as determined by medical history, physical examination

  • normal Pap smear at or documented within 24 months of screening

Study Design

Total Participants: 251
Study Start date:
April 17, 2012
Estimated Completion Date:
October 05, 2012

Connect with a study center

  • TKL Clincial Research Organisation

    Rochelle Park, New Jersey
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.